GF Fund Management’s Apellis Pharmaceuticals APLS Stock Holding History

GF Fund Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,841	Closed	-$114K	–	591
2026 Q1	$114K	Buy	2,841 +356	+14%	+$7.67K	﹤0.01%	328
2025 Q4	$62.4K	Sell	2,485 -232	-9%	-$5.44K	﹤0.01%	388
2025 Q3	$61.5K	Sell	2,717 -468	-15%	-$10.9K	﹤0.01%	375
2025 Q2	$55.1K	Hold	3,185	–	–	﹤0.01%	405
2025 Q1	$69.7K	Buy	3,185 +573	+22%	+$15.8K	﹤0.01%	393
2024 Q4	$83.3K	Buy	+2,612	New	+$78.5K	﹤0.01%	343

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GF Fund Management's APLS Position: Q2 2026 in Review

GF Fund Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 2,841 shares — an estimated $114K sold.

GF Fund Management first reported a position in APLS in Q4 2024 and held it in 6 quarters. The position peaked at $114K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

GF Fund Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
GF Fund Management sold 2,841 Apellis Pharmaceuticals shares in Q2 2026, an estimated $114K.
GF Fund Management first reported a position in Apellis Pharmaceuticals in Q4 2024 and held it in 6 quarters.
GF Fund Management's Apellis Pharmaceuticals position peaked at $114K in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.